Please use this identifier to cite or link to this item:
Title: What is the best contemporary treatment for in-stent restenosis?
Austin Authors: Barlis, Peter;Horrigan, Mark ;Chan, Robert K ;Ajani, Andrew E;Proimos, George;Schumer, Wendy A;van Gaal, William J;Rowe, Michael;Eccleston, David;Yan, Bryan B P;Mun Cheong, Yu;Oliver, Les E;Clark, David J 
Affiliation: Department of Cardiology, Austin Hospital, Studley Road, PO Box 5555, Heidelberg, Victoria 3084, Australia
Issue Date: 12-Oct-2005
Publication information: Cardiovascular Revascularization Medicine : Including Molecular Interventions; 6(4): 179-81
Abstract: In-stent restenosis (ISR) remains a challenging problem in percutaneous coronary intervention and the optimal treatment strategy remains unclear. The aim of this study was to compare the 18 month clinical outcomes in patients receiving sirolimus-eluting stents (SES) with vascular brachytherapy (VBT) for the treatment of ISR. Twenty-five consecutive patients treated with VBT were compared with 29 patients who had SES deployment for ISR. Major adverse cardiac events (MACE) were defined as a combination of death from cardiac causes, nonfatal myocardial infarction, or repeat TVR. At 18 month follow-up, the MACE rate was significantly lower in the SES compared with the VBT group (14% vs 40%, P=.03). One patient in the VBT group developed late stent thrombosis (at 10 months) and died; there was no stent thrombosis in the SES group. This observational study, taken with other recent reports, offers further credence to the use of SES for ISR. The results of randomized comparisons with VBT are awaited with interest.
DOI: 10.1016/j.carrev.2005.10.001
Journal: Cardiovascular revascularization medicine : including molecular interventions
Type: Journal Article
Subjects: Aged
Blood Vessel Prosthesis Implantation.instrumentation
Coated Materials, Biocompatible
Coronary Angiography
Coronary Restenosis.radiography.therapy.ultrasonography
Decision Making
Follow-Up Studies
Immunosuppressive Agents.therapeutic use
Retrospective Studies
Sirolimus.therapeutic use
Treatment Outcome
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.